Abstract:e14513 Background: Local recurrence of Hepatocellular Carcinoma (HCC) following potentially curative resection or ablation is an inevitable risk. T cells recognizing neoantigens are present in most cancers including HCC and offer a specific and highly immunogenic target for the personalized vaccination as an adjuvant therapy. The purpose of this study is to evaluate the safety and T cell immune response of a personalized neoantigen-based mRNA loaded dendritic cell (DC) vaccine (LK101) combined with regular ablation in patients with HCC (NCT03674073). Methods: Each patient’s fresh tumor biopsy and matched peripheral blood sample were subjected to whole-exome sequencing and RNA-sequencing. Following determination of somatic mutations and gene expression, up to 30 in silico–predicted potential neoantigens were selected with bioinformatic tool. DCs were generated from the monocytes enriched by leukapheresis, followed by transfection with neoantigen-encoding mRNA through electroporation. In total, 7 doses of LK101 were administered at 1.5×107 cells/injection intradermally with 4-dose priming weekly and 3 boosters in 4-week intervals. The primary endpoint of the clinical study was safety, and key secondary endpoints were immunogenicity, overall survival and recurrence. 24 HCC patients at HKLC stage IIa were enrolled 1:1 to ablation control arm and ablation combined with DC (LK101) arm. Results: The study was completed, patients were followed up for a median of 48.4 months and 38.8 months in vaccination arm and control arm. All of adverse events were Grade 1-2. Most frequent treatment-related adverse events are injection site reactions, inclusive of local pain (63.6%), itch (27.3%) and others (27.3%), such as redness and edema. 3 patients in ablation control arm died, whereas all vaccinated patients survived. The 1-year and 2-year recurrence rates in vaccination arm compared with control arm are 18.2%, respectively. LK101 induced neoantigen-specific T cell responses were investigated by ELISpot analysis. Overall, all patients elicited at least one measurable response. Immune responses to 60-90% of neoantigen peptides were seen post vaccination across patients. Both preexisting immune response and De Novo immune response that targeted neoantigens were observed in vaccinated patients. Moreover, both CD4 and CD8 positive effector memory T cells showed the trend of increase, and PD-1 positive T cells reduced in peripheral blood of patients after vaccination. Conclusions: Combination of LK101 with ablation therapy has a manageable safety profile, showing the evidence of immune activation and potential of prolonged survival. In combination with regular ablation, neoantigen based mRNA loaded DC vaccine is a promising immunotherapy for the treatment of HCC. Clinical trial information: NCT03674073 .

Induction of Specific Cytolytic T Lymphocytes Using Fusions of Hepatocellular Carcinoma (HCC) Patient-Derived Dendritic Cells and Allogeneic HCC Cell Line.

Eliciting specific antitumor immunity against hepatocellular carcinoma in vitro by fusions of HCC patient-derived dendritic cells with HCC cells

[Inducing Hepatocellular Carcinoma-Specific Cytotoxic T Lymphocyte Response Using Formed by Fusion of FastDCs and Allogeneic Human Hepatocellular Carcinoma Cells].

Comparative analysis of DC fused with allogeneic hepatocellular carcinoma cell line HepG2 and autologous tumor cells as potential cancer vaccines against hepatocellular carcinoma

A Potential Antitumor Effect of Dendritic Cells Fused with Cancer Stem Cells in Hepatocellular Carcinoma

Antitumor Effect of Immunizations with Fusions of Dendritic and Hepatocellular Carcinoma Cells in Mice

Dendritic cells transfected with tumor total RNA induce specific immune responses against hepatocellular carcinoma in vitro

Immunotherapy of Patient with Hepatocellular Carcinoma Using Cytotoxic T Lymphocytes Ex Vivo Activated with Tumor Antigen-Pulsed Dendritic Cells

Dendritic cells transfected with hepatocellular carcinoma (HCC) total RNA induce specific immune responses against HCC in vitro and in vivo

Dendritic Cells Pulsed with Α‐fetoprotein and Mutant P53 Fused Gene Induce Bi‐targeted Cytotoxic T Lymphocyte Response Against Hepatic Carcinoma

Induction of Specific Immune Response Against Hepatocellular Carcinoma by Human SLC and AFP Vector Transfected Dendritic Cells from CD34+ Hematopoietic Stem Cells

The Induction of Specific Anti-Tumor Immunity Against Hepatocellular Carcinoma in Vitro by Using Murine Interleukin-12 Gene-Modified Dendritic Cells

Induction of Antitumor Cytotoxic Lymphocytes Using Engineered Human Primary Blood Dendritic Cells.

A First-in-human Study to Evaluate a Personalized Neoantigen-Based Mrna-Loaded Dendritic Cell Vaccine, in Combination with Ablation, in Patients with Hepatocellular Carcinoma.

Dendritic Cells Loaded with Ultrasound-Ablated Tumour Induce in Vivo Specific Antitumour Immune Responses

Antitumor Effect of Immunization with Fusion of Dendritic Cells and Hepatocellular Carcinoma Cells in Mice.

Effect of Dendritic Cell-Based Immunotherapy on Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.

Dendritic cells fused with allogeneic breast cancer cell line induce tumor antigen-specific CTL responses against autologous breast cancer cells

Cytokine-induced Killer Cells Combined with Dendritic Cells Inhibited Liver Cancer Cells.

Dendritic Cells-Mediated CTLs Targeting Hepatocellular Carcinoma Stem Cells

Autogeneic Rna-Electroporated CD40-ligand Activated B-Cells from Hepatocellular Carcinoma Patients Induce CD8+ T-cell Responses Ex Vivo.